Status:
COMPLETED
A Clinical Trial To Assess Fesoterodine On Treatment Satisfaction And Symptom Improvement In Overactive Bladder Patients
Lead Sponsor:
Pfizer
Conditions:
Overactive Bladder
Eligibility:
All Genders
18+ years
Phase:
PHASE3
Brief Summary
To evaluate the effect of fesoterodine on patient satisfaction and overactive bladder (OAB) symptom relief in OAB patients who were dissatisfied with their prior therapy with tolterodine.
Eligibility Criteria
Inclusion
- OAB patients who present with OAB symptoms(≥8 micturitions and ≥3 urgency episodes per 24 h documented in the baseline bladder diary)
- OAB patients dissatisfied with their prior therapy with tolterodine
Exclusion
- Patients with any contraindication to fesoterodine usage, e.g., urinary retention, gastric retention, uncontrolled narrow-angle glaucoma, or known hypersensitivity to the drug or its ingredients.
- Patients with significant hepatic and renal disease or other significant unstable diseases.
- OAB symptoms caused by neurological conditions, known pathologies of urinary tract, etc.
Key Trial Info
Start Date :
January 1 2007
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
October 1 2007
Estimated Enrollment :
516 Patients enrolled
Trial Details
Trial ID
NCT00425100
Start Date
January 1 2007
End Date
October 1 2007
Last Update
December 5 2018
Active Locations (60)
Enter a location and click search to find clinical trials sorted by distance.
1
Pfizer Investigational Site
Homewood, Alabama, United States, 35209
2
Pfizer Investigational Site
Huntsville, Alabama, United States, 35801
3
Pfizer Investigational Site
La Mesa, California, United States, 91942
4
Pfizer Investigational Site
Orangevale, California, United States, 95662